Panacea Life Sciences Holdings Inc's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Panacea Life Sciences Holdings Inc (EXDI) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Panacea Life Sciences Holdings Inc vs Its Competitors
- TTM: Trailing 12-month revenue of 3M vs -M combined for tracked competitors (100.0% combined share).
- Trending: Latest-quarter revenue run-rate is accelerating (+52.9% annualized vs trailing 12 months).
- Peer revenue share: Panacea Life Sciences Holdings Inc accounted for 100.0% of combined revenue among its tracked peer group, up from 100.0% a year earlier.
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
EXDI Sales vs. its Competitors, Q1 2024
Panacea Life Sciences Holdings Inc generated 100.00 % of the combined sales of its peer group, up from 100.00 % a year earlier.
For context: the Legal Cannabis industry grew revenue 35.0% year over year, combined, vs 55.9% for Panacea Life Sciences Holdings Inc. Panacea Life Sciences Holdings Inc's share of combined industry revenue moved from 0.03% to 0.03%, a gain of 0.00 percentage points.
Panacea Life Sciences Holdings Inc's Competitor Quality Breadth
Share of each group, trailing 12 months: profitable (net margin > 0), expanding (revenue growth > 0), growing faster than the industry's own median, and financially distressed (Piotroski F-Score of 2 or below).
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Panacea Life Sciences Holdings Inc | No | Yes | Yes | No |
| Competitors combined (1) | ||||
| High-Confidence Competitors (1) | ||||
| Similar Growth & Profitability (8) | 0.00 % (0 of 8) | 62.50 % (5 of 8) | 50.00 % (4 of 8) | 42.90 % (3 of 7) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
EXDI Stock Performance relative to its Competitors
EXDI Stock Performance relative to High-Confidence Competitors
EXDI Stock Performance relative to Similar Growth & Profitability Competitors
Publicly Traded Peers of Panacea Life Sciences Holdings Inc
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
| Panacea Life Sciences Holdings Inc | 1.34 | 2.76 |
| Clearday Inc | 0.00 | 7.54 |
| SUBTOTAL | 1.34 | 10.31 |
Sources: Panacea Life Sciences Holdings Inc's official press releases and regulatory filings; CSIMarket.com's market research; and the financial filings and press releases of the other companies cited.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Panacea Life Sciences Holdings Inc versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Panacea Life Sciences Holdings Inc's Competitors Named by the Company
Competitive relationships identified from SEC filings and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| C2M | Named by the company | 85% |
| Cargill | Named by the company | 85% |
| Tyson Foods | Named by the company | 85% |
Filing basis, confidence, active dates and source counts for Panacea Life Sciences Holdings Inc's named competitors require a Commercial License.
Methodology: relationships are extracted from SEC filings (named-competitor disclosures) and corroborating sources. Named by the company = explicitly disclosed as a competitor; Inferred = derived from corroborating signals. Confidence reflects evidence strength.
Panacea Life Sciences Holdings Inc's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Panacea Life Sciences Holdings Inc | 1 | 251,266 | -697,280 |
| Clearday Inc | 0 | - | - |
| PEERS TOTAL | 0 | - | - |
Panacea Life Sciences Holdings Inc's Profitability & Cost Structure
Trailing 12-month margins from SEC-filed financials. Operating margin is compared to the Legal Cannabis industry median; gross margin, EBITDA margin and capital intensity are compared to the live industry average (36 companies).| Metric | Company | Industry | Difference |
|---|---|---|---|
| Gross Margin | 56.53 % | 38.25 % (avg) | +18.3 pp |
| Operating Margin | -192.25 % | industry median | -172.6 pp |
| EBITDA Margin | -189.95 % | -0.49 % (avg) | -189.5 pp |
| Capital Intensity (Capex / Revenue) | 1.99 % | 3.73 % (avg) | -1.7 pp |
Source: CSIMarket API, trailing 12 months. SG&A and R&D as a share of revenue have limited coverage as this data is backfilled and appear only where reported. Higher capital intensity is not inherently negative; it reflects the industry's asset requirements.
Panacea Life Sciences Holdings Inc's Multi-Year Financial Trajectory
Fiscal-year revenue growth, operating margin, return on invested capital and P/E, as reported in SEC filings.| Metric | 2017 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Revenue Growth | - | - | 499.11 % | - | -21.00 % | 46.59 % |
| Operating Margin | - | -3,146.97 % | -509.65 % | - | -347.41 % | -232.55 % |
| Return on Invested Capital | 543.48 % | -105.61 % | 341.96 % | -36.56 % | -56.04 % | 224.51 % |
| P/E | - | - | - | - | - | - |
Source: CSIMarket API, fiscal-year figures. P/E is this company's own historical ratio at each fiscal year end and can swing sharply around an earnings trough: that is real, not a data error.
Panacea Life Sciences Holdings Inc's Strategic Group Map
Every company in Panacea Life Sciences Holdings Inc's industry and named-competitor list, plotted by trailing 12-month revenue growth and operating margin. Panacea Life Sciences Holdings Inc is shown in red; its closest peers by combined growth, margin and ROIC (the Similar Growth & Profitability group above) are labeled.
Source: CSIMarket API, trailing 12 months. Extreme outlier values (from near-zero-revenue companies) are excluded from the plotted cloud but never from the highlighted company or its labeled peers.
Panacea Life Sciences Holdings Inc's Competitive Forces (Porter's Five Forces)
Only the forces this data can support honestly are shown; the other three are marked as such rather than guessed.| Force | Assessment | Basis |
|---|---|---|
| Barriers to Entry | Lower than typical for the industry | Capital intensity (capex / revenue) of 1.99 % vs industry average 3.73 % (see Profitability & Cost Structure above) |
| Supplier Power | Not covered on this page | See Panacea Life Sciences Holdings Inc's dedicated suppliers page for concentration and dependency data |
| Buyer Power | Not covered on this page | See Panacea Life Sciences Holdings Inc's dedicated customers page for concentration and dependency data |
| Threat of Substitutes | - | No systematic data source for cross-product substitution exists in this system; not estimated |
Note: this is a partial, data-grounded application of the framework, not a complete strategic assessment. Rivalry and barriers-to-entry readings are mechanical translations of the HHI and capital-intensity figures shown elsewhere on this page, not independent judgments.
Panacea Life Sciences Holdings Inc's Industry Attractiveness & Competitive Strength
A CSIMarket composite, not a standard field: each axis is an equal-weighted average of three factors already shown elsewhere on this page (industry growth, industry profitability and rivalry for attractiveness; relative market share, profitability and growth vs industry for strength). Disclosed as a designed methodology, not a precision measurement.
Panacea Life Sciences Holdings Inc falls in the Low attractiveness / Medium strength cell: Harvest.
Source: CSIMarket API, trailing 12 months. Each axis score is a simple 1(low)/2(medium)/3(high) average across its three inputs -- a transparent, disclosed simplification, not a validated academic scoring model.
Panacea Life Sciences Holdings Inc's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
- Return on equity 125.9 points above the industry aggregate.
- Latest-quarter revenue run-rate is accelerating (+52.9% annualized vs trailing 12 months).
Weaknesses
- Operating margin 172.6 points below the industry median.
Opportunities
- A meaningful share of tracked competitors (100.00 %) show financial-distress signals, a possible opening to gain share.
Threats
No rule matched.
Methodology: mechanical, rule-based SWOT. Each bullet reuses a figure already sourced and cited elsewhere on this page; nothing here is generated narrative or independent analyst judgment.
Panacea Life Sciences Holdings Inc's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Panacea Life Sciences Holdings Inc | 0.00 | 0.28 | - |
| Clearday Inc | 0.00 | 0.01 | - |
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Panacea Life Sciences Holdings Inc's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Panacea Life Sciences Holdings Inc | Q1 2024 | +55.9 % | - |
| Clearday Inc | Q3 2023 | -72.8 % | - |
| PEERS TOTAL | -49.4 % | - |
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Panacea Life Sciences Holdings Inc's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Panacea Life Sciences Holdings Inc | Q1 2024 | -13.6 % | -67.1 % |
| Clearday Inc | Q3 2023 | - | - |
Panacea Life Sciences Holdings Inc's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Panacea Life Sciences Holdings Inc | - | - | - |
| Clearday Inc | - | - | - |
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Panacea Life Sciences Holdings Inc's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Panacea Life Sciences Holdings Inc | - | 0.48 |
| Clearday Inc | - | 0.00 |
| PEERS AVERAGE | - | 0.13 |
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.